https://mindmedicinelaw.com/briefing/psychedelics-in-treating-substance-use-disorders-emerging-research-20260721-24811The Psychedelic Journalen2026-07-22T22:04:44.843498+00:00Psychedelics in Treating Substance Use Disorders: Emerging Researchpsychedelics, substance use disorders, psilocybin, ketamine, treatment protocols, clinical trials, neuroplasticity, serotonin receptors, policy implications, longitudinal studieshttps://mindmedicinelaw.com/briefing/lilly-s-2-8b-psychedelic-investment-a-new-era-in-trials-20260721-24427The Psychedelic Journalen2026-07-21T15:04:58.867415+00:00Lilly's $2.8B Psychedelic Investment: A New Era in TrialsLilly psychedelic investment, psychedelic clinical trials, neuroplasticity, FDA psychedelic regulation, psychedelic therapy innovation, Schedule I drugs, mental health treatments, pharmaceutical industry, psilocybin research, MDMA trialshttps://mindmedicinelaw.com/briefing/distinct-neural-mechanisms-of-ketamine-s-analgesic-and-dissociative-effects-20260720-24814The Psychedelic Journalen2026-07-22T22:05:25.285349+00:00Distinct Neural Mechanisms of Ketamine's Analgesic and Dissociative Effectsketamine, analgesia, dissociation, neural mechanisms, pain management, psychiatric disorders, fMRI study, placebo-controlled, default mode network, anterior insulahttps://mindmedicinelaw.com/briefing/psilocybin-s-impact-on-dendritic-signaling-and-serotonin-receptors-20260720-24849The Psychedelic Journalen2026-07-22T22:05:16.631304+00:00Psilocybin's Impact on Dendritic Signaling and Serotonin Receptorspsilocybin, dendritic signaling, serotonin receptors, 5-HT2A receptor, psychedelic research, structural plasticity, mental health therapy, neuroscience, clinical trials, behavioral statehttps://mindmedicinelaw.com/briefing/ibogaine-s-potential-in-ketamine-use-disorder-treatment-20260720-24850The Psychedelic Journalen2026-07-22T22:04:53.388867+00:00Ibogaine's Potential in Ketamine Use Disorder Treatmentibogaine treatment, ketamine use disorder, substance use disorder, neuroplasticity, clinical trials, psychedelic therapy, polysubstance dependence, public health, NMDA antagonism, controlled trialshttps://mindmedicinelaw.com/briefing/eli-lilly-s-3-8b-investment-in-psychedelic-medicine-20260720-24936The Psychedelic Journalen2026-07-22T22:04:36.145903+00:00Eli Lilly's $3.8B Investment in Psychedelic Medicineeli lilly, psychedelic medicine, big pharma, clinical trials, mental health, research and development, regulatory approval, psilocybin, MDMA, pharmaceutical investmenthttps://mindmedicinelaw.com/briefing/understanding-trd-multi-pillar-approach-in-neuroscience-20260720-24352The Psychedelic Journalen2026-07-21T22:05:41.823937+00:00Understanding TRD: Multi-Pillar Approach in Neurosciencetreatment-resistant depression, multi-pillar framework, antidepressant efficacy, neurological pillars, clinical trials, neuroscience research, TRD treatment strategies, public health implications, psychiatric disorders, mental health treatmenthttps://mindmedicinelaw.com/briefing/new-framework-for-treatment-resistant-depression-multi-pillar-approach-20260720-24354The Psychedelic Journalen2026-07-21T22:05:30.682716+00:00New Framework for Treatment-Resistant Depression: Multi-Pillar Approachtreatment-resistant depression, multi-pillar approach, neural systems, SSRIs, SNRIs, TCA-1, pharmacological strategies, clinical trials, neuroscience, depression treatmenthttps://mindmedicinelaw.com/briefing/substance-trends-in-drivers-victoria-australia-study-20260720-24416The Psychedelic Journalen2026-07-21T15:05:47.159422+00:00Substance Trends in Drivers: Victoria, Australia Studysubstance use trends, MDMA, methylamphetamine, THC, Victoria Australia, road safety, public health policy, driving impairment, toxicology reports, substance-impaired drivinghttps://mindmedicinelaw.com/briefing/ketamine-s-antidepressant-effects-role-of-cx3cl1-cx3cr1-signaling-20260720-24353The Psychedelic Journalen2026-07-21T15:05:31.074881+00:00Ketamine's Antidepressant Effects: Role of CX3CL1/CX3CR1 Signalingketamine, CX3CL1, CX3CR1, antidepressant effects, synaptic plasticity, mood disorders, neuroscience, clinical trials, chemokines, depression treatmenthttps://mindmedicinelaw.com/briefing/hybrid-group-therapy-model-for-psilocybin-in-terminal-care-20260720-24305The Psychedelic Journalen2026-07-21T15:05:20.739083+00:00Hybrid Group Therapy Model for Psilocybin in Terminal Carepsilocybin-assisted therapy, hybrid group therapy, terminally ill patients, public health interventions, community support, psychedelic research, end-of-life care, peer support, group dynamics, clinical trialshttps://mindmedicinelaw.com/briefing/distinct-neural-correlates-of-ketamine-analgesia-and-dissociation-20260720-24412The Psychedelic Journalen2026-07-21T15:05:09.626675+00:00Distinct Neural Correlates of Ketamine Analgesia and Dissociationketamine, analgesia, dissociation, neural correlates, pain management, clinical trials, neuroscience, therapeutic use, side effects, targeted therapieshttps://mindmedicinelaw.com/briefing/nigerian-medicinal-plants-drug-discovery-prospects-and-challenges-20260717-23670The Psychedelic Journalen2026-07-21T22:06:13.283952+00:00Nigerian Medicinal Plants: Drug Discovery Prospects and Challengesnigerian medicinal plants, drug discovery, psychotropic activities, ethnopharmacology, bioactive compounds, research collaboration, standardization, clinical trials, international research, pharmacological studieshttps://mindmedicinelaw.com/briefing/psychedelic-research-and-mysticism-implications-and-biases-20260717-23735The Psychedelic Journalen2026-07-21T22:06:06.252532+00:00Psychedelic Research and Mysticism: Implications and Biasespsychedelic research, mysticism, scientific rigor, bias in research, subjective experiences, ethical considerations, research policy, neuroscience, LSD, psilocybinhttps://mindmedicinelaw.com/briefing/integrated-ptsd-and-sud-treatment-for-adolescents-evidence-and-future-20260717-23644The Psychedelic Journalen2026-07-21T22:05:55.128316+00:00Integrated PTSD and SUD Treatment for Adolescents: Evidence and Futureintegrated treatment, PTSD, substance use disorder, adolescents, Risk Reduction Through Family Therapy, RRFT, clinical trials, trauma-focused therapy, COPE-A, mental healthhttps://mindmedicinelaw.com/briefing/phenomenology-of-ruminations-implications-for-psychiatry-20260716-24359The Psychedelic Journalen2026-07-21T22:06:24.146644+00:00Phenomenology of Ruminations: Implications for Psychiatryruminations, phenomenology, psychiatric research, cognitive processes, psychedelics, therapeutic approaches, lifeworld analysis, mental health, clinical implications, qualitative researchhttps://mindmedicinelaw.com/briefing/fda-s-new-psychedelic-trial-guidance-impacts-and-implications-20260715-24428The Psychedelic Journalen2026-07-21T15:04:46.056119+00:00FDA's New Psychedelic Trial Guidance: Impacts and ImplicationsFDA guidance, psychedelic trials, clinical trial design, drug development, mental health therapies, regulatory framework, safety monitoring, efficacy assessment, market dynamics, psychedelic researchhttps://mindmedicinelaw.com/briefing/tripartite-model-for-depression-in-oud-clinical-implications-20260713-22503The Psychedelic Journalen2026-07-22T15:05:57.398648+00:00Tripartite Model for Depression in OUD: Clinical Implicationstripartite model, opioid use disorder, depression, substance-induced depression, independent mood disorder, addiction-related depression, clinical practice, dual disorders, therapeutic strategies, diagnostic clarityhttps://mindmedicinelaw.com/briefing/idfa-model-a-new-approach-to-opioid-relapse-prevention-20260713-22494The Psychedelic Journalen2026-07-22T15:05:46.363246+00:00IDFA Model: A New Approach to Opioid Relapse Preventioninformational dysregulation framework, opioid use disorder, relapse prevention, neuroscience, clinical research, computational psychiatry, addiction treatment, information processing, public health policy, mechanism-informed interventionhttps://mindmedicinelaw.com/briefing/leonotis-leonurus-and-mentha-longifolia-antidepressant-potential-explored-20260713-22502The Psychedelic Journalen2026-07-22T15:05:33.486941+00:00Leonotis leonurus and Mentha longifolia: Antidepressant Potential ExploredLeonotis leonurus, Mentha longifolia, antidepressant potential, computational study, molecular docking, network pharmacology, depression treatment, traditional medicine, experimental validation, neurotransmitter systemshttps://mindmedicinelaw.com/briefing/psilocybin-s-behavioral-and-cellular-effects-implications-for-research-20260712-22388The Psychedelic Journalen2026-07-22T15:06:09.295391+00:00Psilocybin's Behavioral and Cellular Effects: Implications for Researchpsilocybin research, behavioral effects, cellular effects, clinical trials, psychedelic mechanisms, regulatory implications, therapeutic applications, neuroplasticity, serotonin receptors, psychiatric conditionshttps://mindmedicinelaw.com/briefing/alzheimer-s-dementia-new-pharmacological-targets-in-trials-20260710-22498The Psychedelic Journalen2026-07-22T15:06:18.001533+00:00Alzheimer's Dementia: New Pharmacological Targets in TrialsAlzheimer's dementia, pharmacological targets, Phase III trials, amyloid plaques, neurodegenerative diseases, clinical trials, therapeutic strategies, patient safety, cognitive declinehttps://mindmedicinelaw.com/briefing/dmt-s-impact-on-anxiety-and-life-satisfaction-implications-20260708-24933The Psychedelic Journalen2026-07-22T22:05:04.816592+00:00DMT's Impact on Anxiety and Life Satisfaction: ImplicationsDMT, psychedelic therapy, anxiety improvement, life satisfaction, clinical guidelines, mental health treatment, neuroscience, quality of life, depression treatment